Search ARM

ARM Member Profiles



At TxCell, we are dedicated to changing life of chronic refractory autoimmune disease patients by restoring the balance of their immune system with our personalized cellular immunotherapies.

TxCell is developing innovative, personalized, economically viable, cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases. TxCell’s patient-specific, Ag-Treg products provide a unique immunotherapy approach to treating chronic autoimmune, anti-inflammatory diseases. Ag-Tregs actively inhibit inflammation through multiple targets using the natural properties of Treg cells that are radically different from the activity of strategies blocking of a single molecule.

Thanks to its proprietary ASTrIA technology platform, TxCell can “teach” Type 1 T regulatory cells, which have natural anti-inflammatory capabilities, to activate themselves effectively, in a highly targeted manner and without the resistance effects found in today’s treatments.

Our research has led us to develop OVASAVE®, a product which is aimed in particular at Crohn’s disease patients “refractory” to all treatments, of whom there are an estimated 80,000 to 100,000 a year. Our first clinical results have turned out to be very convincing, in terms of both effectiveness and tolerance, which gives us confidence for the future in targeting this market worth an estimated €3 billion. Our second product in full development, Col-Treg, is aimed at the treatment of non-infections uveitis, an orphan indication that is one of the leading cause of blindness in the developed world.

The other major innovation in our technology lies in the production process, which promises to make personalised cellular therapy economically viable. Treg education is undertaken only once based on a simple sample of blood taken from the patient. The “educated” Tregs are then frozen for use in treatment over a number of years. Since the production cost is covered during the first year of treatment, this production process is a highly original factor in TxCell’s business model.

We also have a strategic partnership in for the treatment of chronic inflammatory diseases of the intestine with the Swiss company Ferring International Center, a major pharmaceutical company with a global franchise in the therapeutic area.

TxCell is a public company, quoted on Euronext-Paris (TXCL: FR0010127662).

Contact TxCell
+33(0) 497 218 300
BD & Communication Department Tel: +33(0) 497 218 300 Fax: +33(0) 493 641 580
Visit Website